Sells insulin pumps and replacement supplies, and offers diabetes data tools for people with diabetes, caregivers and healthcare providers.
10-K for FY2025, filed Feb 19, 2026
Supplies and other products are the largest sales stream; people with third-party insurance and distributors buy these products and pumps. Sales count when products ship to distributors or reach direct customers; software access and support is spread over the pump warranty period.
10-K for FY2025, filed Feb 19, 2026
10-K for FY2025, filed Feb 19, 2026
FY2025 revenue by product or service ↗$1B
10-K for FY2025, filed Feb 19, 2026
$1B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Pump
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
46%
FY2022: 54%
|
Pump, FY2025
$464.1M Sources
|
Sold outright |
|
Supplies and other
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
54%
FY2022: 47%
|
Supplies and other, FY2025
$550.6M Sources
|
Sold outright |
|
Net sales recognized (deferred) for Tandem Choice program
|
0.0%
FY2022: −0.4%
|
Net sales recognized (deferred) for Tandem Choice program, FY2025
$0 Sources
|
People with diabetes buy pumps and supplies through U.S. and international distribution partners; in the U.S. and Canada, Tandem also sells directly, with distributors handling some order fulfillment.
10-K for FY2025, filed Feb 19, 2026Revenue is generated primarily from sales of insulin pumps, single-use insulin cartridges and infusion sets to individual customers with…View ↗
Segment revenues were consistent with revenue reported in the Company’s consolidated statements of operations and comprehensive loss for…View ↗
Our technology solutions are now available in more than 25 countries. In the United States and Canada, we have always employed direct…View ↗
No. It lost $204.7M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$7.1MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Nov 13, 2026
On November 12, 2026, Tandem Diabetes Care, Inc. (the “Company”) received 510(k) clearance from the U.S. Food and Drug Administration for…View ↗
8-K, filed Nov 5, 2026
Sales are estimated to be approximately $1.065 billion to $1.085 billion U.S. sales of approximately $730 million to $745 million…View ↗
Growing. Revenue grew 44% in 4 years, from $702.8M in FY2021 to $1B in FY2025, about 10% a year.
Broader pump lineup
Earlier commercial efforts focused exclusively on the flagship pump; the latest report describes a wider pump portfolio that includes Mobi.
10-K for FY2022, filed Feb 22, 2023 10-K for FY2025, filed Feb 19, 2026Today, our commercial efforts exclusively focus on the manufacturing, sale and support of our flagship pump platform, the t:slim X2 insulin…View ↗
We offer durable insulin pumps that are designed for years of daily use. We sell single-use supplies that are used together with our pumps…View ↗
Competes with Beta Bionics, Insulet, Medtronic, mylife, and Sequel
10-K for FY2025, filed Feb 19, 2026The medical device industry is intensely competitive, subject to rapid change and highly sensitive to the introduction of new products…View ↗
Loading...